- Active Pharmaceutical Ingredients
- Varenicline tartrate
- Aprepitant, Fosapitant Intermediates
- Fosaprepitant Dimeglumine
- Vildagliptin
- Efinaconazole
- Luliconazole Intermediate
- Gadoterate Meglumine
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- Varenicline tartrate 230615-70-0
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Nuclear magnetic resonance imaging agent Gadobutrol 138071-82-6
【Catalog Number 】AP5100
【CAS #】 138071-82-6
【Molecular Formula】C18H31GdN4O9
【Molecular Weight】604.71
English Name :
Gadobutrol
CAS# :
138071-82-6
产品描述
[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[产品参数, 参数]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]
|
Alias |
Gadobutrol |
|
Catalog Number |
AP5100 |
|
CAS # |
138071-82-6 |
|
Molecular Formula |
C18H31GdN4O9 |
|
Molecular Weight |
604.71 |
|
Structural Formula |
|
|
Product Introduction CAS 138071-82-6 |
Gadobutrol, English name is Gadobutrol, American Chemical Abstracts Registration Number is cas 138071-82-6. Gadobutrol (CAS 138071-82-6) is a gadolinium-containing contrast agent introduced by Bayer Pharmaceuticals. This medication is used for magnetic resonance imaging (MRI) examinations of the patient's central nervous system. In addition, succinyl alcohol was approved by the US Food and Drug Administration (FDA) in March 2011. |
扫二维码用手机看
VIWIT 沪ICP备12014533号-2
